Two competing paths for cannabis medicine: whole-plant extracts versus single-molecule drugs
A commentary examines the unique challenges and merits of developing cannabis-based medicines from whole-plant preparations versus synthesized individual cannabinoids, noting how legalization complicates both pathways.
Quick Facts
What This Study Found
Researchers outlined the two parallel approaches to cannabinoid drug development and their respective challenges. The botanical approach derives medications directly from the cannabis plant, offering the potential entourage effect but facing challenges with standardization, batch consistency, and regulatory complexity. The single-molecule approach synthesizes individual cannabinoids for pharmaceutical development, offering precise dosing and regulatory clarity but potentially missing synergistic effects.
Both approaches face unique complications from the expanding legalization of cannabis. Legalization creates a situation where patients can access unregulated cannabis products that compete with pharmaceutical development, potentially undermining the incentive to conduct expensive clinical trials.
The commentary also highlighted regulatory challenges, noting that the botanical approach must navigate agricultural regulation alongside pharmaceutical approval, while the single-molecule approach faces competition from the very plant compounds it seeks to purify. Public health considerations were discussed, including the need for quality control regardless of the regulatory pathway chosen.
Key Numbers
Two development pathways: botanical (plant-derived) and single molecule (synthesized). Two synthetic cannabinoid drugs FDA-approved at time of publication. Multiple state-level legalization programs creating competing access pathways.
How They Did This
This was a commentary discussing the two major cannabinoid drug development strategies, their challenges, and the impact of legalization on pharmaceutical development.
Why This Research Matters
The pathway through which cannabis medicines are developed has direct implications for patients. Whole-plant products may offer broader therapeutic effects through the entourage mechanism, but single-molecule drugs offer more precise dosing and better-studied safety profiles. Understanding this debate helps patients and clinicians make informed choices.
The Bigger Picture
This tension between botanical and pharmaceutical approaches is unique to cannabis medicine. No other plant-based medicine has the same combination of widespread public access, political legalization, and simultaneous pharmaceutical development. How this tension resolves will shape the future of cannabis medicine for decades.
What This Study Doesn't Tell Us
This is a commentary reflecting expert opinions rather than presenting new data. The discussion is framed within the US regulatory context and may not fully apply to other jurisdictions. The commentary was published before several significant regulatory developments.
Questions This Raises
- ?Can the pharmaceutical industry develop profitable cannabis medicines when patients can grow or purchase the plant?
- ?Will botanical standardization ever achieve the consistency required for pharmaceutical-grade products?
- ?How should regulatory frameworks balance access with safety?
Trust & Context
- Key Stat:
- Two competing pathways: botanical vs single-molecule cannabinoid drug development
- Evidence Grade:
- This is an expert commentary providing moderate-level analysis of the drug development landscape.
- Study Age:
- Published in 2018, before several major regulatory developments in cannabinoid medicine.
- Original Title:
- Cannabis and cannabinoid drug development: evaluating botanical versus single molecule approaches.
- Published In:
- International review of psychiatry (Abingdon, England), 30(3), 277-284 (2018)
- Authors:
- Bonn-Miller, Marcel O(23), ElSohly, Mahmoud A(10), Loflin, Mallory J E(3), Chandra, Suman, Vandrey, Ryan
- Database ID:
- RTHC-01599
Evidence Hierarchy
Summarizes existing research on a topic.
What do these levels mean? →Frequently Asked Questions
What is the difference between whole-plant and synthetic cannabis medicine?
Whole-plant (botanical) preparations contain the full spectrum of cannabis compounds and may benefit from the entourage effect. Single-molecule drugs isolate or synthesize individual cannabinoids for precise dosing. Each approach has advantages: botanical for broader effects, single-molecule for standardization and regulatory clarity.
Why does legalization affect cannabis drug development?
When patients can buy cannabis at a dispensary, there is less incentive for companies to invest in expensive clinical trials. This creates a paradox where increased access may actually slow the development of rigorously tested cannabis medicines.
Read More on RethinkTHC
- CBD-oil-quality-guide
- anxiety-medication-after-quitting-weed
- cannabis-chemotherapy-nausea
- cannabis-chronic-pain-research
- cannabis-epilepsy-CBD-Epidiolex
- cbd-anxiety-research-evidence
- cbd-for-weed-withdrawal
- cbd-vs-thc-difference
- medical-benefits-of-cannabis
- quitting-weed-before-surgery
- quitting-weed-medication-interactions
- quitting-weed-pregnancy
- quitting-weed-pregnant
- seniors-older-adults-cannabis-risks-medications
- weed-breastfeeding-THC-breast-milk
Cite This Study
https://rethinkthc.com/research/RTHC-01599APA
Bonn-Miller, Marcel O; ElSohly, Mahmoud A; Loflin, Mallory J E; Chandra, Suman; Vandrey, Ryan. (2018). Cannabis and cannabinoid drug development: evaluating botanical versus single molecule approaches.. International review of psychiatry (Abingdon, England), 30(3), 277-284. https://doi.org/10.1080/09540261.2018.1474730
MLA
Bonn-Miller, Marcel O, et al. "Cannabis and cannabinoid drug development: evaluating botanical versus single molecule approaches.." International review of psychiatry (Abingdon, 2018. https://doi.org/10.1080/09540261.2018.1474730
RethinkTHC
RethinkTHC Research Database. "Cannabis and cannabinoid drug development: evaluating botani..." RTHC-01599. Retrieved from https://rethinkthc.com/research/bonn-miller-2018-cannabis-and-cannabinoid-drug
Access the Original Study
Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.
This study breakdown was produced by the RethinkTHC research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.